Just as the Brisbane Kangaroo Point Bridge provides a modern, adaptive connection over a challenging river, early phase studies require highly tailored and state-of-the-art solutions.

Bridge to Trial, designs agile clinical pathways that are responsive to emerging data and regulatory feedback. Our flexible approach ensures your transition to the clinic is structurally sound, mitigating risk and accelerating potential.

Clinical Development & Trial Management Consulting

Providing end-to-end strategic leadership and operational oversight for early-phase clinical trials (Phase I–IIa), ensuring adherence to GCP, strict timelines, and budget constraints
with specialized expertise in the Australian landscape.

Leveraging the Australian Advantage

Running Phase 1 clinical studies in Australia presents several advantages, delivering unmatched speed and cost-efficiencies while maintaining full regulatory acceptability with the FDA and EMA:

  • Streamlined Regulatory Pathway: No IMPD required, a straightforward online Clinical Trial Notification (CTN) to the TGA, and rapid, commercially predictable Ethics Review with less burdensome queries.
  • Site Readiness: Dedicated Phase 1 units can be activated within weeks following HREC approval.
  • Rapid Timelines: 5 to 8 weeks from final protocol/IB submission to screening start.
  • R&D Tax Incentive: A 43.5% cash rebate on eligible R&D expenditure for companies with an annual aggregate turnover of under AUD $20 million.

Bridge to Trial offers specialized expertise to seamlessly execute your Phase 1 studies in Australia — while remaining fully equipped to support your program across any global jurisdiction.

1. Study Design & Operational Feasibility

  • Protocol Preparation & Review: Thorough preparation or critical review of study protocols to guarantee operational feasibility, sound methodological design, and seamless execution.
  • Timeline Architecture: Development of detailed, robust clinical timelines covering full lifecycle milestones—from study start-up and regulatory/ethics approvals to active conduct and database lock/close-out.
  • Database & Data Management: Expert review of electronic data capture (EDC) database design, review of data validation specifications, and active participation in ongoing clinical data review and cleaning oversight.
Design & Feasibility

2. Clinical Conduct & Safety Oversight

  • Operational Trial Conduct: On-the-ground management of active study conduct, site activation, and recruitment tracking.
  • Medical Monitoring & Safety Interface: Close operational coordination with Medical Monitors, Pharmacovigilance (PV) teams, and Safety Review Committees (SRCs) / Dose Escalation Committees—critical for managing safety signals and dose cohorts in early-phase trials.
Conduct & Safety

3. Regulatory & Compliance Governance

  • Regulatory Submissions: Comprehensive review and coordination of clinical trial applications and regulatory submissions to national authorities and Ethics Committees / Institutional Review Boards (IRBs).
  • Australian Advantages: Strategic guidance on leveraging the Australian regulatory landscape and local pathways to accelerate early-phase development.
  • eTMF Maintenance: Ensuring continuous, inspection-ready maintenance of the Electronic Trial Master File (eTMF) using industry platforms (such as Veeva eTMF).
  • GCP Compliance: Establishing and overseeing rigorous quality standards, audit readiness, and Good Clinical Practice (GCP) compliance across all participating entities.
Regulatory

4. Vendor Management, Contracting & IP Supply

  • CRO & Site Selection: Full-cycle management of Contract Research Organizations (CROs) and clinical investigation sites.
  • Contracting & CTAs: Drafting, review, and negotiation of critical vendor contracts and Clinical Trial Agreements (CTAs).
  • External Partner Coordination: Seamless operational coordination with specialized third-party vendors, including safety laboratories, bioanalytical testing facilities, and independent biometric/statistical teams.
  • IP Supply Chain & Accountability: Oversight of Investigational Product (IP) distribution, cold-chain logistics, pharmacy manuals, and rigorous clinical supply accountability across sites.
Vendors & IP

5. Financial & Scope Governance

  • Budget Management & Forecasting: Comprehensive financial oversight, tracking actuals against projected milestone payments, and managing clinical trial budgets.
  • Scope Management & Change Control: Proactive management of project scope and structured change control, including protocol amendments and study design adaptations driven by emerging clinical data.
Financial & Scope

6. Risk Management & Quality Oversight

  • Proactive Risk Planning: Implementation of robust risk-management frameworks aligned with ICH GCP E6 (R3), identifying critical-to-quality factors and potential operational vulnerabilities early in the development lifecycle.
  • Mitigation & Monitoring: Designing and executing targeted risk-mitigation strategies, oversight plans, and continuous quality controls across clinical sites and vendors.
Risk & Quality

7. Reporting & Trial Closure

  • Clinical Study Report (CSR): Critical review and medical/operational contribution to final Clinical Study Reports.
  • Study Close-Out: Execution of orderly site and vendor close-out activities, final financial reconciliation, and archival handover.
Close-Out & CSR

How We Deliver Value

By combining rigorous scientific insight—grounded in advanced chemical and translational expertise—with seasoned clinical project management, financial discipline, and proactive risk governance, we eliminate the operational silos between your non-clinical package and first-in-human execution. We help you maintain essential flexibility in early-phase trials while keeping timelines tight, budgets controlled, and quality inspection-ready. Let us help you de-risk your asset and accelerate your clinical program with confidence.